Clinical Trials Logo

Neoplasm Recurrence, Local clinical trials

View clinical trials related to Neoplasm Recurrence, Local.

Filter by:

NCT ID: NCT05475301 Completed - Rectal Neoplasms Clinical Trials

Incidence, Risk Factor, Treatment and Overall Survival of Locally Recurrent Rectal Cancer

Start date: January 1, 2015
Phase:
Study type: Observational [Patient Registry]

Data on disease recurrence was collected for all primary rectal cancer patients diagnosed in the Netherlands over the first six months of 2015. Three-year cumulative incidence, risk factors, treatment and three-year OS of locally recurrent rectal cancer were determined.

NCT ID: NCT05475288 Completed - Colonic Neoplasms Clinical Trials

Incidence, Risk Factor, Treatment and Overall Survival of Locoregionally Recurrent Colon Cancer

Start date: January 1, 2015
Phase:
Study type: Observational [Patient Registry]

Data on disease recurrence was collected for all primary colon cancer patients diagnosed in the Netherlands over the first six months of 2015. Three-year cumulative incidence, risk factors, treatment and three-year OS of locoregionally recurrent colon cancer were determined.

NCT ID: NCT05121805 Recruiting - Polyps of Colon Clinical Trials

Recurrences After Standard EMR vs Plus Thermal Ablation EMR

RESPECT
Start date: March 17, 2022
Phase: N/A
Study type: Interventional

The primary objective of this trial is to investigate whether thermal ablation EMR with soft tip snare coagulation (STSC) reduces the recurrence rate of lateral spreading or sessile polyps ≥20mm compared to standard EMR.

NCT ID: NCT04239365 Completed - Colorectal Cancer Clinical Trials

Follow-up Protocol of Colorectal Endoscopic Mucosal Resection Scars

Start date: January 31, 2020
Phase: N/A
Study type: Interventional

Nowadays endoscopic mucosal resection (EMR) is the gold standard for the removal of large laterally spreading and sessile colorectal lesions ≥ 20 mm. However, recurrence rate after successful EMR (defined by the absence of neoplastic tissue at the completion of the procedure after careful inspection of the post-EMR mucosal defect and margin) is about 15-20%. Consequently, current guidelines recommend a surveillance colonoscopy between 4 and 6 months after resection for detection of residual or recurrent polyp. There are few studies that have examined the accuracy of advanced endoscopic imaging for the prediction of histological recurrence but none of these imaging modalities have been validated for surveillance after EMR. Therefore, current guidelines strongly recommend systematic biopsy of EMR scar. The main aim of this study is to assess the incremental benefit of narrow band imaging (NBI) and white light endoscopy (WLE) randomizing the initial technique for the endoscopic detection of post-EMR recurrence and to asses if this advanced imaging method achieve sufficient diagnostic accuracy to exclude recurrence without the need for biopsy.

NCT ID: NCT03833960 Completed - Clinical trials for Sentinel Lymph Node Biopsy

SLNB After Neoadjuvant Treatment in Node Positive Patients

Start date: May 2016
Phase:
Study type: Observational

From May 2016 till May 2018 all breast cancer patients with operable disease submitted to surgery after neoadjuvant treatment would be divided in four groups considering initially clinical axillary stage, axillary procedure that was done, axillary response to preoperative systemic treatment and pathological axillary stage. In first postoperative year all patients will be monitored for appearance of locoregional and distant recurrence.

NCT ID: NCT03646955 Recruiting - Pain Clinical Trials

Partial Breast Versus no Irradiation for Women With Early Breast Cancer

Start date: September 5, 2018
Phase: N/A
Study type: Interventional

All early breast cancer patients are offered adjuvant breast radiation therapy (RT) after breast conserving surgery for an early breast cancer. Breast cancer is heterogeneous, and selected patients have a very low gain from RT, whilst they still have risk of acute and late side effects from RT. This trial will try identify selection criteria for low risk breast cancer patients who can safely omit adjuvant RT without unacceptable high risk of local failure.

NCT ID: NCT03583619 Completed - Breast Neoplasms Clinical Trials

Randomized Trial of Accelerated Partial Breast Irradiation

Start date: July 19, 2017
Phase: N/A
Study type: Interventional

This study is to compare radiation toxicity of accelerated partial breast irradiation (ABPI) with whole breast irradiation (WBI) in low-risk breast cancer.

NCT ID: NCT03583580 Recruiting - Breast Neoplasms Clinical Trials

Accelerated Partial Breast Irradiation With IMRT in Early Breast Cancer

Start date: June 19, 2017
Phase: N/A
Study type: Interventional

This study is to evaluate the efficacy and toxicity of accelerated partial breast irradiation (ABPI) with intensity modulated radiation therapy (IMRT) in low-risk breast cancer treat with breast-conserving surgery.

NCT ID: NCT02801409 Completed - Lung Cancer Clinical Trials

Epidural Anesthesia-analgesia and Long-term Survival After Lung Cancer Surgery

Start date: May 25, 2015
Phase: N/A
Study type: Interventional

Available studies suggest that regional anesthesia-analgesia may decrease the occurrence of recurrence/metastasis in patients after cancer surgery. However, evidences from prospective studies are still lacking. The purpose of this randomized controlled trial is to investigate the effect of epidural anesthesia-analgesia on recurrence-free survival in patients undergoing lung cancer surgery.

NCT ID: NCT02087475 Recruiting - Surgery Clinical Trials

Perioperative FOLFIRI VS Adjuvant FOLFIRI in Resectable Advanced CRC Failed to Oxaliplatin

Start date: January 2011
Phase: Phase 3
Study type: Interventional

Colorectal cancer (CRC) is one of the most leading causes of cancer death in China. Although multiple treatment modalities including surgery, radiotherapy and chemotherapy have been developed, the prognosis of advanced CRC still remains poor. While around 30% of resectable advanced CRC could be cured. This study is designed to compare perioperative FOLFIRI versus adjuvant FOLFIRI in resectable advanced CRC who exposed to oxaliplatin in open-label, phase III mode.